Skip to main content

Table 2 Comparison of patients with P. aeruginosa without mutation vs with mutation Bacteriological data

From: Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients

  No mutation
n= 119
Mutation
n=34
p
Prior ICU colonization no/yes 98 (82.4%) / 21 (17.6%) 27 (79.4%) / 7 (20.6%) 0.801
Infection with P. aeruginosa no/yes 46 (38.7%) / 73 (61.3%) 4 (11.8%) / 30 (88.2%) 0.003*
Other infections no/yes 36 (30.3%) / 83 (69.7%) 5 (14.7%) / 29 (85.3%) 0.081
Initial resistance no/yes 23 (19.3%) / 96 (80.7%) 15 (44.1%) / 19 (55.9%) 0.006*
Type of initial resistance to β-lactamines
 1= impermeability 1 (0.8%) 2 (5.9%) 0.005*
 3= Penicillinase and/or efflux 45 (37.8%) 11 (32.4%)
 4= AmpC over-production 10 (8.4%) 0 (0%)
 5= impermeability +/- Over-production of efflux 9 (7.6%) 4 (11.8%)
 6= 4+5 25 (21%) 1 (2.9%)
Fluoroquinolone resistance no/yes 74 (62.2%) / 45 (37.8%) 25 (73.5%) / 9 (26.5%) 0.309
Aminoglycoside resistance no/yes 94 (79%) / 25 (21%) 34 (100%) / 0 (0%) 0.001*
Antibiotic therapy after isolation of P. aeruginosa
P. aeruginosa ATB 1 adapted (n=97) no/yes 10 (14.9%) / 57 (85.1%) 2 (6.7%) / 28 (93.3%) 0.332
P. aeruginosa ATB 2 adapted (n=66) no/yes 2 (5%) / 38 (95%) 0 (0%) / 26 (100%) 0.515
P. aeruginosa ATB 3 adapted (n=28) no/yes 0 (0%) / 13 (100%) 2 (13.3%) / 13 (86.7%) 0.484
 Tazocillin after P. aeruginosa no/yes 94 (79%) / 25 (21%) 23 (67.6%) / 11 (32.4%) 0.176
 Ceftazidime after P. aeruginosa no/yes 95 (79.8%) / 24 (20.2%) 19 (55.9%) / 15 (44.1%) 0.007*
 Cefepime after P. aeruginosa no/yes 101 (84.9%) / 18 (15.1%) 30 (88.2%) /4 (11.8%) 0.785
 Meropenem after P. aeruginosa no/yes 79 (66.4%) / 40 (33.6%) 15 (44.1%) / 19 (55.9%) 0.027*
 Fluoroquinolone after P. aeruginosa no/yes 115 (96.6%) / 4 (3.4%) 34 (100%) / 0 (0%) 0.576
 Aminoglycosides after P. aeruginosa no/yes 57 (47.9%) / 62 (52.1%) 8 (23.5%) / 26 (76.5%) 0.017*
  1. * signify that it is considered to be statistically significant with p < 0.05